QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, November 9, 2005, 25(45):10502-10509; doi:10.1523/JNEUROSCI.3016-05.2005

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (19) Citing Articles via Google Scholar Google Scholar Articles by Gonzalez-Alegre, P. Articles by Paulson, H. L. Search for Related Content PubMed PubMed Citation Articles by Gonzalez-Alegre, P. Articles by Paulson, H. L.

 Previous Article  |  Next Article 

Neurobiology of Disease
Silencing Primary Dystonia: Lentiviral-Mediated RNA Interference Therapy for DYT1 Dystonia

Pedro Gonzalez-Alegre,¹ Nicole Bode,¹ Beverly L. Davidson,^1,2 and Henry L. Paulson¹

Departments of ¹Neurology and ²Medicine, Carver College of Medicine at the University of Iowa, Iowa City, Iowa 52242

DYT1 is the most common inherited dystonia. Currently, there are no preventive or curative therapies for this dominantly inherited disease. DYT1 dystonia is caused by a common three-nucleotide deletion in the TOR1A gene that eliminates a glutamic acid residue from the protein torsinA. Recent studies suggest that torsinA carrying the disease-linked mutation, torsinA(E) acts through a dominant-negative effect by recruiting wild-type torsinA [torsinA(wt)] into oligomeric structures in the nuclear envelope. Therefore, suppressing torsinA(E) expression through RNA interference (RNAi) could restore the normal function of torsinA(wt), representing a potentially effective therapy regardless of the biological role of torsinA. Here, we have generated short hairpin RNAs (shRNAs) that mediate allele-specific suppression of torsinA(E) and rescue cells from its dominant-negative effect, restoring the normal distribution of torsinA(wt). In addition, delivery of this shRNA by a recombinant feline immunodeficiency virus effectively silenced torsinA(E) in a neural model of the disease. We further establish the feasibility of this viral-mediated RNAi approach by demonstrating significant suppression of endogenous torsinA in mammalian neurons. Finally, this silencing of torsinA is achieved without triggering an interferon response. These results support the potential use of viral-mediated RNAi as a therapy for DYT1 dystonia and establish the basis for preclinical testing in animal models of the disease.

Key words: dystonia; RNA interference; torsina; dyt1; gene therapy; FIV

---

Received July 21, 2005; revised September 23, 2005; accepted October 6, 2005.

This article has been cited by other articles:

				R. D. Klootwijk, P. J. M. Savelkoul, C. Ciccone, I. Manoli, N. J. Caplen, D. M. Krasnewich, W. A. Gahl, and M. Huizing Allele-specific silencing of the dominant disease allele in sialuria by RNA interference FASEB J, November 1, 2008; 22(11): 3846 - 3852. [Abstract] [Full Text] [PDF]

				M. D. White, M. Farmer, I. Mirabile, S. Brandner, J. Collinge, and G. R. Mallucci Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease PNAS, July 22, 2008; 105(29): 10238 - 10243. [Abstract] [Full Text] [PDF]

				J. W. Hewett, F. C. Nery, B. Niland, P. Ge, P. Tan, P. Hadwiger, B. A. Tannous, D. W.Y. Sah, and X. O. Breakefield siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells Hum. Mol. Genet., May 15, 2008; 17(10): 1436 - 1445. [Abstract] [Full Text] [PDF]

				J. L. McBride, R. L. Boudreau, S. Q. Harper, P. D. Staber, A. M. Monteys, I. Martins, B. L. Gilmore, H. Burstein, R. W. Peluso, B. Polisky, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi PNAS, April 15, 2008; 105(15): 5868 - 5873. [Abstract] [Full Text] [PDF]

				A. Jagannath and M. Wood RNA interference based gene therapy for neurological disease Brief Funct Genomic Proteomic, May 3, 2007; (2007) elm005v1. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help